- Home
- SMHI vs IPHA Comparison
SMHI vs IPHA Comparison
Compare SMHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- IPHA
- Stock Information
- Founded
- SMHI 1989
- IPHA 1999
- Country
- SMHI United States
- IPHA France
- Employees
- SMHI N/A
- IPHA N/A
- Industry
- SMHI Marine Transportation
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SMHI Consumer Discretionary
- IPHA Health Care
- Exchange
- SMHI Nasdaq
- IPHA Nasdaq
- Market Cap
- SMHI 189.9M
- IPHA 148.3M
- IPO Year
- SMHI N/A
- IPHA 2019
- Fundamental
- Price
- SMHI $6.89
- IPHA $1.77
- Analyst Decision
- SMHI
- IPHA Strong Buy
- Analyst Count
- SMHI 0
- IPHA 1
- Target Price
- SMHI N/A
- IPHA $11.50
- AVG Volume (30 Days)
- SMHI 162.3K
- IPHA 42.3K
- Earning Date
- SMHI 02-27-2025
- IPHA 09-12-2024
- Dividend Yield
- SMHI N/A
- IPHA N/A
- EPS Growth
- SMHI N/A
- IPHA N/A
- EPS
- SMHI N/A
- IPHA N/A
- Revenue
- SMHI $274,636,000.00
- IPHA $36,202,722.00
- Revenue This Year
- SMHI $6.04
- IPHA N/A
- Revenue Next Year
- SMHI $11.18
- IPHA $101.65
- P/E Ratio
- SMHI N/A
- IPHA N/A
- Revenue Growth
- SMHI 3.89
- IPHA N/A
- 52 Week Low
- SMHI $5.80
- IPHA $1.29
- 52 Week High
- SMHI $15.36
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SMHI 52.97
- IPHA 46.55
- Support Level
- SMHI $6.90
- IPHA $1.65
- Resistance Level
- SMHI $7.37
- IPHA $1.87
- Average True Range (ATR)
- SMHI 0.35
- IPHA 0.12
- MACD
- SMHI 0.07
- IPHA -0.03
- Stochastic Oscillator
- SMHI 62.20
- IPHA 33.47
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides world-wide marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations including wind farms; handle anchors and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico); Africa and Europe; Middle East and Asia and Latin America.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.